Current Research Trials

Georgia Pollens Clinical Research Centers, Inc.
105 Spanish Court, Albany, Georgia 31707
Telephone: 229-883-8909 Fax: 229-317-0609

BAXALTA 161406—A Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA: Ages ≥16 years and older who have been prescribed or started on Hyqvia. Visit swill be coordinated with office visits and/or every 3 months.
(Length of trial = 52 weeks, with the potential to continue for an additional year depending on blood results)
Compensation to participants: $25 after each completed visit.

Genentech GB39242--Protocol Title: GB39242: A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA Ages 18--75 years; (BMI) of 18−35 kg/m2 and weight ≥ 40 kg at screening; On ICS therapy at a total daily dose ≥ 500 µg of fluticasone propionate or equivalent plus at least one additional allowed controller medication, for ≥ 3 months prior to screening, with no changes within 4 weeks prior to screening; **Documented history of at least one asthma exacerbation within 12 months prior to screening while on daily ICS maintenance therapy (same dose as at screening**; Documented physician-diagnosed asthma for at least 12 months prior to screening Morning pre-bronchodilator FEV1 of 40%−80% of predicted at the screening and run-in (Week 0) visits. **This sponsor is having a VERY difficult time enrolling globally.**
(Length of trial = 70 weeks, not including a 3 week run-in period)
Compensation to participants: $75 after each completed visit or for 18 visits.

GlaxoSmithKline 204959--An open-label study to evaluate the use of an **autoinjector (3 doses self-administered)** for the subcutaneous administration of mepolizumab (Nucala) in subjects with severe eosinophilic asthma. **Ages 12 years and older** with a ≥ 2 year documented history of asthma. Two groups of patients may participate: **#1** For those patients already receiving 100 mg SC mepolizumab administered every 4 weeks **for at least 12 weeks prior to Visit 1**. **#2** Other patients must be on a stable dose of ICS ≥880 mcg/day fluticasone propionate (FP) (ex-actuator) or equivalent daily. (For those participants 12- 17 years, ICS dose must be ≥440 mcg/day FP (ex-actuator) or equivalent daily.) Must be on an additional controller medication for at least 3 months and have at least one documented asthma exacerbation in the previous 12 months. **Trial will move fast so we do not want to "sit on" any potential participants that meet the criteria.**
Compensation to participants: $75 after each completed visit (6 visits).

LeoPharma LP0162-1325 ECZTRA-- Tralokinumab monotherapy for moderate-to-severe atopic dermatitis **in subjects 18 years and older.** Diagnosis of atopic dermatitis for ≥ 1 year. The trial is as follows: two screening visits with 20 weeks of double-blind Tralokinumab; followed by 34 weeks of open-label Tralokinumab treatment and a 16-week short-term extension period of open-label Tralokinumab and a FINAL follow-up visit. MULTIPLE skin scoring assessments at each visit preferably by the initial clinician.
Compensation to participants: $75 after each completed visit, every 2 weeks ("potential" to have 39 total visits).

Radar PGx (a Patient Registry) a PGx test assessment (molecular biomarker) in the medication regimen and disease management for patients under drugs known to be influenced by genetic variation and who have experienced an adverse drug reaction (see attached list) within the previous 24 month period
(Length of trial = 120 days)
Compensation to participants: $10 after each mouth swab and/or visit.

Updated: April 13, 2017